Clinician-guided care in Westlake, Ohio
Peptide options, explained with clarity.
Every ASR peptide treatment shown here is compounded. Explore the directory by whether a separate FDA-approved counterpart exists, then schedule a clinical consultation to discuss suitability and current availability.
Two clear categories
Know what kind of medication you are considering.
FDA approval applies to a specific drug product, formulation, route, and labeled indication. The groups below distinguish compounded ASR treatments with an approved counterpart from those without one.
Compounded Peptides with FDA-Approved Counterparts
FDA has approved a separate product containing the active ingredient. ASR's compounded preparation is not that approved product.
Compounded & Investigational Peptides
No FDA-approved product counterpart was found under the audited treatment name. Evidence limitations and known safety concerns are stated plainly.
Treatment directory
Find a treatment to discuss with your provider.
All treatments are compounded. Final availability and suitability are determined through ASR's clinical evaluation.
27 treatments shown
Semaglutide
ASR's compounded preparation is not FDA-approved. FDA-approved semaglutide products include Ozempic, Rybelsus, and Wegovy, each with specific labeled uses.
Tirzepatide
ASR's compounded preparation is not FDA-approved. FDA-approved tirzepatide products include Mounjaro and Zepbound, each with specific labeled uses.
Tesamorelin
ASR's compounded preparation is not FDA-approved. FDA approval belongs to Egrifta products and their specific labeled indication.
Bremelanotide / PT-141
ASR's compounded PT-141 preparation is not FDA-approved. Vyleesi is an FDA-approved bremelanotide product with a narrow labeled indication.
Elamipretide / SSR-31
ASR's compounded SSR-31 preparation is not FDA-approved. Forzinity has a specific approval for qualifying patients with Barth syndrome.
Sermorelin
Previously approved Geref products are discontinued. ASR's compounded Sermorelin preparation is not FDA-approved.
AOD-9604
No FDA-approved counterpart was identified. FDA has cited inadequate safety information and potential significant risks for compounded use.
BPC-157
No FDA-approved counterpart was identified. FDA has cited limited safety information and potential immunogenicity and characterization risks.
CJC-1295
No FDA-approved counterpart was identified. FDA reports limited clinical data and serious adverse events associated with CJC-1295.
CJC-1295 + Ipamorelin
No FDA-approved combination product was identified. The compounded combination is not FDA-approved, and both components require careful risk review.
DSIP / Emideltide
No FDA-approved counterpart was identified. FDA states that it lacks sufficient safety information for compounded emideltide.
Epitalon
No FDA-approved counterpart was identified. Human safety information is limited, so longevity claims require careful qualification.
GHK-Cu
No FDA-approved injectable counterpart was identified. Injectable use should not be confused with topical cosmetic products.
GHRP-2
No FDA-approved counterpart was identified. FDA has identified potential significant safety risks for injectable and nasal compounded use.
GHRP-6
No FDA-approved counterpart was identified. FDA has identified potential significant safety risks for compounded use.
Ipamorelin
No FDA-approved counterpart was identified. FDA has cited immunogenicity, impurity, and serious-adverse-event concerns.
Kisspeptin
No FDA-approved counterpart was identified for the clinic product. The exact peptide form and route must be reviewed during consultation.
KPV
No FDA-approved counterpart was identified. FDA states that it has not identified human exposure data for KPV drug products.
LL-37 / Cathelicidin
No FDA-approved counterpart was identified. FDA reports insufficient safety information and concerning nonclinical findings.
Melanotan II
No FDA-approved counterpart was identified. FDA cites published serious-adverse-event reports and other safety concerns.
MOTS-C
No FDA-approved counterpart was identified. FDA states that it has not identified human exposure data for MOTS-C drug products.
PEG-MGF
No FDA-approved counterpart was identified. FDA states that it has not identified human exposure data for PEG-MGF drug products.
Retatrutide
Retatrutide is investigational and is not FDA-approved. Availability and current regulatory status must be confirmed during consultation.
Selank
No FDA-approved counterpart was identified. FDA has cited immunogenicity and peptide-impurity concerns and inadequate human safety information.
Semax
No FDA-approved counterpart was identified. FDA has cited immunogenicity and peptide-impurity concerns and inadequate safety information.
TB-500
No FDA-approved counterpart was identified. FDA reports a lack of identified human exposure data and potential safety risks.
Thymosin Alpha-1
No U.S. FDA-approved counterpart was identified. FDA states that available safety information is inadequate for compounded thymosin alpha-1.
Important medication notice
A consultation determines what is appropriate - not a webpage.
Compounded drugs are not FDA-approved, and FDA does not verify their safety, effectiveness, or quality before marketing. Genevieve George, PA-C, evaluates each patient before prescribing and reviews the product, alternatives, limitations, and informed consent.
Personalized medical consultation
Bring your goals. Leave with a clearer understanding of your options.
Your provider will review your health history, the exact medication source, possible benefits, limitations, alternatives, and risks before recommending any treatment.